《Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis》
礼来（Eli Lilly）值得买入，该股被低估，预计未来12至18个月将上涨约30%。
尽管礼来是第二家推出用于减重治疗的口服片剂的公司，但它已经开始获得可观的市场份额。该公司在口服GLP-1药物领域的新增用药人群中占据了超过30%的市场份额，识别出超过36,000人。
Although Eli Lilly was the second company to introduce oral pills for weight loss treatments, it had already begun to acquire a significant market share. The company boasted a market share exceeding 30% in new initiations within the oral GLP-1 drug sector , identifying more than 36,000 people.